Crosstalk between AMPK activation and angiotensin II-induced hypertrophy in cardiomyocytes: The role of mitochondria

Journal of Cellular and Molecular Medicine

Volumn 18, Issue 4, 2014, Pages 709-720

  Hernández, Jessica Soto ^a   Barreto Torres, Giselle ^a   Kuznetsov, Andrey V ^b   Khuchua, Zaza ^c   Javadov, Sabzali ^a  

^a UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c UNIVERSITY OF CINCINNATI   (United States)

Author keywords

AMP kinase; Angiotensin II receptors; Hypertrophy; Metformin; Mitochondria

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN II; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LOSARTAN; METFORMIN; NOS3 PROTEIN, RAT; PROTEIN P53; SIRT1 PROTEIN, RAT; SIRTUIN 1;

ANIMAL; BIOSYNTHESIS; CARDIOMEGALY; DRUG EFFECTS; GENE EXPRESSION REGULATION; HEART MUSCLE CELL; METABOLISM; MITOCHONDRION; PATHOLOGY; RAT; SIGNAL TRANSDUCTION;

AMP-ACTIVATED PROTEIN KINASES; ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; CARDIOMEGALY; GENE EXPRESSION REGULATION; LOSARTAN; METFORMIN; MITOCHONDRIA; MYOCYTES, CARDIAC; NITRIC OXIDE SYNTHASE TYPE III; RATS; RECEPTOR, ANGIOTENSIN, TYPE 1; SIGNAL TRANSDUCTION; SIRTUIN 1; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84897959639     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12220     Document Type: Article

References (44)

1. Hardie DG, Hawley SA, Scott JW. AMP-activated protein kinase-development of the energy sensor concept. J Physiol. 2006; 574: 7-15.
2. Arad M, Seidman CE, Seidman JG. AMP-activated protein kinase in the heart: role during health and disease. Circ Res. 2007; 100: 474-88.
3. Bertrand L, Ginion A, Beauloye C, et al. AMPK activation restores the stimulation of glucose uptake in an in vitro model of insulin-resistant cardiomyocytes via the activation of protein kinase B. Am J Physiol Heart Circ Physiol. 2006; 291: H239-50.
4. Zhang L, He H, Balschi JA. Metformin and phenformin activate AMP-activated protein kinase in the heart by increasing cytosolic AMP concentration. Am J Physiol Heart Circ Physiol. 2007; 293: H457-66.
5. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med. 2002; 137: 25-33.
6. Gundewar S, Calvert JW, Jha S, et al. Activation of AMP-activated protein kinase by metformin improves left ventricular function and survival in heart failure. Circ Res. 2009; 104: 403-11.
7. Sasaki H, Asanuma H, Fujita M, et al. Metformin prevents progression of heart failure in dogs: role of AMP-activated protein kinase. Circulation. 2009; 119: 2568-77.
8. Molkentin JD, Dorn GW 2nd. Cytoplasmic signaling pathways that regulate cardiac hypertrophy. Annu Rev Physiol. 2001; 63: 391-426.
9. Reid IA. Interactions between ANG II, sympathetic nervous system, and baroreceptor reflexes in regulation of blood pressure. Am J Physiol. 1992; 262: E763-78.
10. Siragy HM. AT(1) and AT(2) receptors in the kidney: role in disease and treatment. Am J Kidney Dis. 2000; 36: S4-9.
11. Liu Q, Wang G, Zhou G, et al. Angiotensin II-induced p53-dependent cardiac apoptotic cell death: its prevention by metallothionein. Toxicol Lett. 2009; 191: 314-20.
12. Dai DF, Rabinovitch P. Mitochondrial oxidative stress mediates induction of autophagy and hypertrophy in angiotensin-II treated mouse hearts. Autophagy. 2011; 7: 917-8.
13. Barreto-Torres G, Parodi-Rullan R, Javadov S. The role of PPARalpha in metformin-induced attenuation of mitochondrial dysfunction in acute cardiac ischemia/reperfusion in rats. Int J Mol Sci. 2012; 13: 7694-709.
14. Hawley SA, Gadalla AE, Olsen GS, et al. The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. Diabetes. 2002; 51: 2420-5.
15. Cook JL, Re RN. Lessons from in vitro studies and a related intracellular angiotensin II transgenic mouse model. Am J Physiol Regul Integr Comp Physiol. 2012; 302: R482-93.
16. Lei B, Matsuo K, Labinskyy V, et al. Exogenous nitric oxide reduces glucose transporters translocation and lactate production in ischemic myocardium in vivo. Proc Natl Acad Sci USA. 2005; 102: 6966-71.
17. Bolli R. Cardioprotective function of inducible nitric oxide synthase and role of nitric oxide in myocardial ischemia and preconditioning: an overview of a decade of research. J Mol Cell Cardiol. 2001; 33: 1897-918.
18. Jugdutt BI. Nitric oxide in heart failure: friend or foe. Heart Fail Rev. 2002; 7: 385-9.
19. Sartoretto JL, Kalwa H, Pluth MD, et al. Hydrogen peroxide differentially modulates cardiac myocyte nitric oxide synthesis. Proc Natl Acad Sci USA. 2011; 108: 15792-7.
20. Fujita T, Ishikawa Y. Apoptosis in heart failure. -The role of the beta-adrenergic receptor-mediated signaling pathway and p53-mediated signaling pathway in the apoptosis of cardiomyocytes. Circ J. 2011; 75: 1811-8.
21. Grishko V, Pastukh V, Solodushko V, et al. Apoptotic cascade initiated by angiotensin II in neonatal cardiomyocytes: role of DNA damage. Am J Physiol Heart Circ Physiol. 2003; 285: H2364-72.
22. Langley E, Pearson M, Faretta M, et al. Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence. EMBO J. 2002; 21: 2383-96.
23. Vaziri H, Dessain SK, Ng Eaton E, et al. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell. 2001; 107: 149-59.
24. Wolff S, Erster S, Palacios G, et al. p53's mitochondrial translocation and MOMP action is independent of Puma and Bax and severely disrupts mitochondrial membrane integrity. Cell Res. 2008; 18: 733-44.
25. Vaseva AV, Marchenko ND, Ji K, et al. p53 opens the mitochondrial permeability transition pore to trigger necrosis. Cell. 2012; 149: 1536-48.
26. Yin M, van der Horst IC, van Melle JP, et al. Metformin improves cardiac function in a nondiabetic rat model of post-MI heart failure. Am J Physiol Heart Circ Physiol. 2011; 301: H459-68.
27. Russell RR 3rd, Li J, Coven DL, et al. AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. J Clin Invest. 2004; 114: 495-503.
28. Fu YN, Xiao H, Ma XW, et al. Metformin attenuates pressure overload-induced cardiac hypertrophy via AMPK activation. Acta Pharmacol Sin. 2011; 32: 879-87.
29. Kodiha M, Rassi JG, Brown CM, et al. Localization of AMP kinase is regulated by stress, cell density, and signaling through the MEK-ERK1/2 pathway. Am J Physiol Cell Physiol. 2007; 293: C1427-36.
30. Salt I, Celler JW, Hawley SA, et al. AMP-activated protein kinase: greater AMP dependence, and preferential nuclear localization, of complexes containing the alpha2 isoform. Biochem J. 1998; 334: 177-87.
31. Schuhmacher S, Foretz M, Knorr M, et al. alpha1AMP-activated protein kinase preserves endothelial function during chronic angiotensin II treatment by limiting Nox2 upregulation. Arterioscler Thromb Vasc Biol. 2011; 31: 560-6.
32. van Kesteren CA, van Heugten HA, Lamers JM, et al. Angiotensin II-mediated growth and antigrowth effects in cultured neonatal rat cardiac myocytes and fibroblasts. J Mol Cell Cardiol. 1997; 29: 2147-57.
33. Nagata D, Takeda R, Sata M, et al. AMP-activated protein kinase inhibits angiotensin II-stimulated vascular smooth muscle cell proliferation. Circulation. 2004; 110: 444-51.
34. Stuck BJ, Lenski M, Bohm M, et al. Metabolic switch and hypertrophy of cardiomyocytes following treatment with angiotensin II are prevented by AMP-activated protein kinase. J Biol Chem. 2008; 283: 32562-9.
35. Jiang SY, Xu M, Ma XW, et al. A distinct AMP-activated protein kinase phosphorylation site characterizes cardiac hypertrophy induced by L-thyroxine and angiotensin II. Clin Exp Pharm Physiol. 2010; 37: 919-25.
36. Feng X, Luo Z, Ma L, et al. Angiotensin II receptor blocker telmisartan enhances running endurance of skeletal muscle through activation of the PPAR-delta/AMPK pathway. J Cell Mol Med. 2011; 15: 1572-81.
37. Marques MB, Ribeiro-Oliveira A Jr, Guimaraes J, et al. Modifications in basal and stress-induced hypothalamic AMP-activated protein kinase (AMPK) activity in rats chronically treated with an angiotensin II receptor blocker. Stress. 2012; 15: 554-61.
38. Pierzchalski P, Reiss K, Cheng W, et al. p53 Induces myocyte apoptosis via the activation of the renin-angiotensin system. Exp Cell Res. 1997; 234: 57-65.
39. Nelson LE, Valentine RJ, Cacicedo JM, et al. A novel inverse relationship between metformin-triggered AMPK-SIRT1 signaling and p53 protein abundance in high glucose-exposed HepG2 cells. Am J Physiol Cell Physiol. 2012; 303: C4-13.
40. Ota H, Eto M, Ogawa S, et al. SIRT1/eNOS axis as a potential target against vascular senescence, dysfunction and atherosclerosis. J Atheroscler Thromb. 2010; 17: 431-5.
41. Jin BY, Sartoretto JL, Gladyshev VN, et al. Endothelial nitric oxide synthase negatively regulates hydrogen peroxide-stimulated AMP-activated protein kinase in endothelial cells. Proc Natl Acad Sci USA. 2009; 106: 17343-8.
42. Rakhit RD, Marber MS. Nitric oxide: an emerging role in cardioprotection? Heart. 2001; 86: 368-72.
43. Bhamra GS, Hausenloy DJ, Davidson SM, et al. Metformin protects the ischemic heart by the Akt-mediated inhibition of mitochondrial permeability transition pore opening. Basic Res Cardiol. 2008; 103: 274-84.
44. El-Mir MY, Nogueira V, Fontaine E, et al. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem. 2000; 275: 223-8.